In addition to being a potent driver event in numerous cancers, the clinical utility of oncogenic mutation of KRAS has been reported in the context of prognosis of poor survival outcomes, diagnosis of malignancy, and prediction of response and/or acquired resistance to both chemotherapy and targeted therapies against EGFR (i.e., TKIs) and, very recently, PD‐L1‐based checkpoint inhibition (Hames et al, 2016; Dong et al, 2017; Hirsch et al, 2017; Zhuang et al, 2017; Román et al, 2018). Here, KRAS is linked to cancer.